Synonyms: BA058 | Tymlos®
abaloparatide is an approved drug (FDA (2017))
Compound class:
Peptide
Comment: Abaloparatide is a synthetic analogue of the 34 amino-terminal residues of human parathyroid hormone-related protein (PTHrP) [1]. Compare this to the approved drug teriparatide which is a synthetic analogue of human parathyroid hormone (PTH). Abaloparatide and teriparatide are synthetic peptides that help grow and strengthen bone.
|
No information available. |
Summary of Clinical Use ![]() |
The FDA granted abaloparatide approval in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Results from Phase 3 trial NCT01343004 evaluating abaloparatide has shown a reduced risk of new bone fractures in postmenopausal women receiving abaloparatide injection compared to placebo, with slight benefit over the already approved PTH analogue drug teriparatide [2]. There was also reduced incidence of hypercalcemia among women taking abaloparatide compared to those allocated to the teriparatide arm of the trial. |